세계 희귀질환 시장 규모는 2034년까지 연평균 8.8%의 성장률을 나타낼 것으로 예상됩니다.
R&D의 발전과 규제적 인센티브가 시장 성장을 견인할 것입니다.
희귀질환 시장은 다양한 요인에 의해 성장 궤도와 영향력을 형성하고 있습니다. 가장 중요한 촉진요인 중 하나는 의료 전문가, 정책 입안자 및 일반 대중의 희귀질환에 대한 인식과 이해가 높아지고 있다는 점입니다. 이러한 인식 증가는 조기 진단, 치료 접근성 향상, 환자 및 가족 지원 네트워크의 확대로 이어집니다.
R&D의 발전은 공공 및 민간 부문의 투자에 힘입어 희귀질환의 치료 환경을 지속적으로 확장하고 있습니다. 유전자 치료, 정밀의료, 희귀질환 치료제 개발 등의 분야에서 획기적인 발전이 이루어지고 있으며, 이는 지금까지 충족되지 않았던 의료 수요를 충족시킬 수 있는 잠재력을 가지고 있습니다.
혁신과 투자를 장려하는 규제적 인센티브와 정책도 희귀질환 시장을 발전시키는 데 중요한 역할을 하고 있습니다. 여기에는 시장 독점권 확대, 신속한 심사 절차, 의약품 개발에 대한 재정적 인센티브 등이 포함됩니다. 또한, 의료의 세계화와 신흥국을 중심으로 한 새로운 시장의 출현은 희귀질환 치료제에 대한 접근성과 시장 확대의 기회를 제공합니다.
세계 희귀질환 시장을 조사했으며, 시장 개요, 규제 환경, 파이프라인 분석, 시장 성장에 영향을 미치는 요인 및 시장 기회 분석, 시장 규모 추이 및 예측, 각 부문별/지역별/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.
목차
제1장 보고서 개요
제2장 주요 요약
제3장 시장 개요
주요 조사 결과
시장 역학
영향 분석
시장 추진 요인
시장 성장 억제요인
시장 기회
규제 프레임워크
신흥 시장과 메가트렌드
Porter의 Five Forces 분석
PEST 분석
파이프라인 분석
제4장 희귀질환 시장 분석 : 질환별
주요 조사 결과
시장의 매력 지수
시장 규모 추이와 예측
암
대사성 질환
신경 질환
혈액 질환
감염증
근골격 장애
심혈관 질환
기타
시장 규모 추이와 예측 : 지역별
시장 점유율 : 지역별
제5장 희귀질환 시장 분석 : 유형별
주요 조사 결과
시장의 매력 지수
시장 규모 추이와 예측
비생물제제
생물제제
시장 규모 추이와 예측 : 지역별
시장 점유율 : 지역별
제6장 희귀질환 시장 분석 : 최종사용자별
주요 조사 결과
시장의 매력 지수
시장 규모 추이와 예측
전문 약국
병원 약국
소매 약국
시장 규모 추이와 예측 : 지역별
시장 점유율 : 지역별
제7장 희귀질환 시장 분석 : 연령층별
주요 조사 결과
시장의 매력 지수
시장 규모 추이와 예측
성인
소아
시장 규모 추이와 예측 : 지역별
시장 점유율 : 지역별
제8장 희귀질환 시장 분석 : 지역별
주요 조사 결과
시장 규모 추이와 예측
제9장 북미의 희귀질환 시장 분석
제10장 유럽의 희귀질환 시장 분석
제11장 아시아태평양의 희귀질환 시장 분석
제12장 라틴아메리카의 희귀질환 시장 분석
제13장 중동 및 아프리카의 희귀질환 시장 분석
제14장 기업 개요
경쟁 구도
Novartis AG
Teva Pharmaceutical Industries Ltd.
AbbVie Inc.
Alexion Pharmaceuticals, Inc.(AstraZeneca)
Amgen Inc.
Biogen Inc.
F. Hoffmann-La Roche Ltd.
Johnson &Johnson Services, Inc.
Merck &Co Inc.
Pfizer Inc.
Sanofi
Takeda Pharmaceutical Company Limited.
Bristol-Myers Squibb Company
Amneal Pharmaceuticals LLC
Dr. Reddy's Laboratories Ltd.
Chiesi Farmaceutici S.p.A.
Vertex Pharmaceuticals Incorporated
제15장 결론 및 제안
Visiongain의 결론
시장 진출기업에 대한 제안
LSH
영문 목차
영문목차
The global Rare Diseases market is projected to grow at a CAGR of 8.8% by 2034
The Rare Diseases Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Advancements in R&D and Regulatory Incentives Driving Market Growth
The rare diseases market is driven by a convergence of factors that collectively shape its growth trajectory and impact. One pivotal driver is the increasing awareness and understanding of rare diseases among healthcare professionals, policymakers, and the general public. This heightened awareness leads to earlier diagnosis, improved access to treatment, and expanded support networks for patients and families.
Advancements in research and development, fuelled by both public and private investment, continuously expand the therapeutic landscape for rare diseases. Breakthroughs in areas such as gene therapy, precision medicine, and orphan drug development hold promise for addressing previously unmet medical needs.
Regulatory incentives and policies that encourage innovation and investment play a significant role in driving the rare diseases market forward. These include extended market exclusivity, expedited review processes, and financial incentives for drug development. Furthermore, the globalization of healthcare and the emergence of new markets, particularly in developing countries, present opportunities for market expansion and access to rare disease treatments. Collectively, these driving factors underscore the dynamic and multifaceted nature of the rare diseases market, fuelled by a commitment to improving outcomes for patients facing these challenging conditions.
High Entry Barriers Likely to Challenge Industry Growth
High entry barriers pose a significant challenge to the growth of the rare diseases market. The substantial costs and lengthy timelines associated with research and development deter new entrants, limiting competition and innovation. Additionally, stringent regulatory requirements and complex reimbursement processes further hinder market entry for potential therapies. These barriers create a formidable challenge for companies seeking to develop and commercialize treatments for rare diseases, constraining market growth and potentially limiting patient access to new therapies.
What Questions Should You Ask before Buying a Market Research Report?
How is the rare diseases market evolving?
What is driving and restraining the rare diseases market?
How will each rare diseases submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
How will the market shares for each rare diseases submarket develop from 2024 to 2034?
What will be the main driver for the overall market from 2024 to 2034?
Will leading rare diseases markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
Who are the leading players and what are their prospects over the forecast period?
What are the rare diseases projects for these leading companies?
How will the industry evolve during the period between 2024 and 2034? What are the implications of rare diseases projects taking place now and over the next 10 years?
Is there a greater need for product commercialisation to further scale the rare diseases market?
Where is the rare diseases market heading and how can you ensure you are at the forefront of the market?
What are the best investment options for new product and service lines?
What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the rare diseases market today, and over the next 10 years:
The report highlights key lucrative areas in the industry so you can target them - NOW.
It contains in-depth analysis of global, regional and national sales and growth.
It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2034 and other analyses reveal commercial prospects
In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
You will find original analyses, with business outlooks and developments.
Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising rare diseases prices and recent developments.
Segments Covered in the Report
Diseases
Cancer
Metabolic Diseases
Neurological Conditions
Hematologic Disorders
Infectious Diseases
Musculoskeletal Disorders
Cardiovascular Disorders
Others
Type
Non Biologics
Biologics
End-users
Specialty Pharmacies
Hospital Pharmacies
Retail Pharmacies
Age Group
Adult
Pediatric
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:
North America
U.S.
Canada
Europe
Germany
UK
France
Spain
Italy
Netherlands
Switzerland
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Malaysia
Singapore
Rest of Asia Pacific
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
MEA
GCC
South Africa
Rest of MEA
The report also includes profiles and for some of the leading companies in the Rare Diseases Market, 2024 to 2034, with a focus on this segment of these companies' operations.
Leading companies profiled in the report
AbbVie Inc.
Alexion Pharmaceuticals, Inc. (AstraZeneca)
Amgen Inc.
Amneal Pharmaceuticals LLC
Biogen Inc.
Bristol-Myers Squibb Company
Chiesi Farmaceutici S.p.A.
Dr. Reddy's Laboratories Ltd.
F. Hoffmann-La Roche Ltd.
Johnson & Johnson Services, Inc.
Merck & Co Inc.
Novartis AG
Pfizer Inc.
Sanofi
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Vertex Pharmaceuticals Incorporated
Overall world revenue for Rare Diseases Market, 2024 to 2034 in terms of value the market will surpass US$200.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Rare Diseases Market, 2024 to 2034 report help you?
In summary, our 340+ page report provides you with the following knowledge:
Revenue forecasts to 2034 for Rare Diseases Market, 2024 to 2034, with forecasts for disease, type, end-users, and age group each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
Revenue forecasts to 2034 for five regional and 25 key national markets - See forecasts for the Rare Diseases Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
Prospects for established firms and those seeking to enter the market - including company profiles for 17 of the major companies involved in the Rare Diseases Market, 2024 to 2034.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Rare Diseases Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.
Table of Contents
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Rare Diseases Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
